149 related articles for article (PubMed ID: 38546643)
41. [Retrospective study of 70 cases with the head and neck non-parameningeal rhabdomyosarcoma].
Zhang G; Wang SC; Su Y; Liu ZK; Yu GX; Zhang J; Mei L; Sun N; Li YZ; Zhang XX; Liu QY; Liu ZY; Li XD; Ni X
Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2024 Feb; 59(2):133-139. PubMed ID: 38369791
[No Abstract] [Full Text] [Related]
42. Alveolar rhabdomyosarcoma with regional nodal involvement: Results of a combined analysis from two cooperative groups.
Gallego S; Chi YY; De Salvo GL; Li M; Merks JHM; Rodeberg DA; van Scheltinga ST; Mascarenhas L; Orbach D; Jenney M; Million L; Minard-Colin V; Wolden S; Zanetti I; Parham DM; Mandeville H; Venkatramani R; Bisogno G; Hawkins DS;
Pediatr Blood Cancer; 2021 Mar; 68(3):e28832. PubMed ID: 33245207
[TBL] [Abstract][Full Text] [Related]
43. Metastatic rhabdomyosarcoma with exclusive distant lymph node involvement: A European Pediatric Soft tissue sarcoma Study Group (EpSSG) report.
Mercolini F; Merks JHM; Minard-Colin V; Cameron A; van Scheltinga SEJT; Sher O; Fichera G; Orbach D; Glosli H; Coppadoro B; Gallego S; Chisholm JC; Bisogno G
Pediatr Blood Cancer; 2023 Mar; 70(3):e30143. PubMed ID: 36519598
[TBL] [Abstract][Full Text] [Related]
44. Localized vaginal/uterine rhabdomyosarcoma-results of a pooled analysis from four international cooperative groups.
Minard-Colin V; Walterhouse D; Bisogno G; Martelli H; Anderson J; Rodeberg DA; Ferrari A; Jenney M; Wolden S; De Salvo G; Arndt C; Merks JHM; Gallego S; Schwob D; Haie-Meder C; Bergeron C; Stevens MCG; Oberlin O; Hawkins D;
Pediatr Blood Cancer; 2018 Sep; 65(9):e27096. PubMed ID: 29781567
[TBL] [Abstract][Full Text] [Related]
45. Genomic and clinical analysis of fusion gene amplification in rhabdomyosarcoma: a report from the Children's Oncology Group.
Duan F; Smith LM; Gustafson DM; Zhang C; Dunlevy MJ; Gastier-Foster JM; Barr FG
Genes Chromosomes Cancer; 2012 Jul; 51(7):662-74. PubMed ID: 22447499
[TBL] [Abstract][Full Text] [Related]
46. Treatment and outcome of patients with localized intrathoracic and chest wall rhabdomyosarcoma: a report of the Cooperative Weichteilsarkom Studiengruppe (CWS).
Fuchs J; Urla C; Sparber-Sauer M; Schuck A; Leuschner I; Klingebiel T; Blumenstock G; Seitz G; Koscielniak E
J Cancer Res Clin Oncol; 2018 May; 144(5):925-934. PubMed ID: 29464349
[TBL] [Abstract][Full Text] [Related]
47. Immunohistochemical detection of PAX-FOXO1 fusion proteins in alveolar rhabdomyosarcoma using breakpoint specific monoclonal antibodies.
Azorsa DO; Bode PK; Wachtel M; Cheuk ATC; Meltzer PS; Vokuhl C; Camenisch U; Khov HL; Bode B; Schäfer BW; Khan J
Mod Pathol; 2021 Apr; 34(4):748-757. PubMed ID: 33299109
[TBL] [Abstract][Full Text] [Related]
48. Prognostic relevance of early radiologic response to induction chemotherapy in pediatric rhabdomyosarcoma: A report from the International Society of Pediatric Oncology Malignant Mesenchymal Tumor 95 study.
Vaarwerk B; van der Lee JH; Breunis WB; Orbach D; Chisholm JC; Cozic N; Jenney M; van Rijn RR; McHugh K; Gallego S; Glosli H; Devalck C; Gaze MN; Kelsey A; Bergeron C; Stevens MCG; Oberlin O; Minard-Colin V; Merks JHM
Cancer; 2018 Mar; 124(5):1016-1024. PubMed ID: 29211298
[TBL] [Abstract][Full Text] [Related]
49. An Increased Risk of Second Malignant Neoplasms After Rhabdomyosarcoma: Population-Based Evidence for a Cancer Predisposition Syndrome?
Archer NM; Amorim RP; Naves R; Hettmer S; Diller LR; Ribeiro KB; Rodriguez-Galindo C
Pediatr Blood Cancer; 2016 Feb; 63(2):196-201. PubMed ID: 26193998
[TBL] [Abstract][Full Text] [Related]
50. Tumor-cell DNA content predicts outcome in children and adolescents with clinical group III embryonal rhabdomyosarcoma. The Intergroup Rhabdomyosarcoma Study Committee of the Children's Cancer Group and the Pediatric Oncology Group.
Pappo AS; Crist WM; Kuttesch J; Rowe S; Ashmun RA; Maurer HM; Newton WA; Asmar L; Luo X; Shapiro DN
J Clin Oncol; 1993 Oct; 11(10):1901-5. PubMed ID: 8410116
[TBL] [Abstract][Full Text] [Related]
51. Metabolic response as assessed by
Harrison DJ; Chi YY; Tian J; Hingorani P; Mascarenhas L; McCowage GB; Weigel BJ; Venkatramani R; Wolden SL; Yock TI; Rodeberg DA; Hayes-Jordan AA; Teot LA; Spunt SL; Meyer WH; Hawkins DS; Shulkin BL; Parisi MT
Cancer Med; 2021 Feb; 10(3):857-866. PubMed ID: 33340280
[TBL] [Abstract][Full Text] [Related]
52. Outcome and prognostic variables in childhood rhabdomyosarcoma (RMS) with emphasis on impact of FOXO1 fusions in non-metastatic RMS: experience from a tertiary cancer centre in India.
Ramanathan S; Sisodiya S; Shetty O; Prasad M; Parambil BC; Shah S; Ramadwar M; Khanna N; Laskar S; Qureshi S; Vora T; Chinnaswamy G
Ecancermedicalscience; 2023; 17():1539. PubMed ID: 37138963
[TBL] [Abstract][Full Text] [Related]
53. Suboptimal outcome for patients with biliary rhabdomyosarcoma treated on low-risk clinical trials: A report from the Children's Oncology Group.
Aye JM; Xue W; Palmer JD; Walterhouse DO; Arnold MA; Heaton TE; Venkatramani R
Pediatr Blood Cancer; 2021 Apr; 68(4):e28914. PubMed ID: 33501771
[TBL] [Abstract][Full Text] [Related]
54. [Clinical analysis of 26 children with postoperative residual or recurrent fibrosarcoma].
Tang JJ; Pan C; Gao YJ; Han YL; Hu WT; Zhang J; Zhou M; Tang JY
Zhonghua Er Ke Za Zhi; 2020 Aug; 58(8):668-673. PubMed ID: 32842388
[No Abstract] [Full Text] [Related]
55. Clinical features and prognosis of paediatric rhabdomyosarcoma with bone marrow metastasis: a single Centre experiences in China.
Huang C; Jian B; Su Y; Xu N; Yu T; He L; Zhang X; Liu Y; Jin M; Ma X
BMC Pediatr; 2021 Oct; 21(1):463. PubMed ID: 34670517
[TBL] [Abstract][Full Text] [Related]
56. Prognostic significance of tumor response at the end of therapy in group III rhabdomyosarcoma: a report from the children's oncology group.
Rodeberg DA; Stoner JA; Hayes-Jordan A; Kao SC; Wolden SL; Qualman SJ; Meyer WH; Hawkins DS
J Clin Oncol; 2009 Aug; 27(22):3705-11. PubMed ID: 19470937
[TBL] [Abstract][Full Text] [Related]
57. Do children and adolescents with completely resected alveolar rhabdomyosarcoma require adjuvant radiation? A report from the Children's Oncology Group.
Aye JM; Chi YY; Tian J; Rudzinski ER; Binitie OT; Dasgupta R; Wolden SL; Hawkins DS; Gupta AA
Pediatr Blood Cancer; 2020 May; 67(5):e28243. PubMed ID: 32124549
[TBL] [Abstract][Full Text] [Related]
58. Clinical Application of Prognostic Gene Expression Signature in Fusion Gene-Negative Rhabdomyosarcoma: A Report from the Children's Oncology Group.
Hingorani P; Missiaglia E; Shipley J; Anderson JR; Triche TJ; Delorenzi M; Gastier-Foster J; Wing M; Hawkins DS; Skapek SX
Clin Cancer Res; 2015 Oct; 21(20):4733-9. PubMed ID: 26473193
[TBL] [Abstract][Full Text] [Related]
59. Improved outcome for patients with middle ear rhabdomyosarcoma: a children's oncology group study.
Hawkins DS; Anderson JR; Paidas CN; Wharam MD; Qualman SJ; Pappo AS; Scott Baker K; Crist WM
J Clin Oncol; 2001 Jun; 19(12):3073-9. PubMed ID: 11408504
[TBL] [Abstract][Full Text] [Related]
60. Circulating Tumor DNA Is Prognostic in Intermediate-Risk Rhabdomyosarcoma: A Report From the Children's Oncology Group.
Abbou S; Klega K; Tsuji J; Tanhaemami M; Hall D; Barkauskas DA; Krailo MD; Cibulskis C; Nag A; Thorner AR; Pollock S; Imamovic-Tuco A; Shern JF; DuBois SG; Venkatramani R; Hawkins DS; Crompton BD
J Clin Oncol; 2023 May; 41(13):2382-2393. PubMed ID: 36724417
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
